HomeCompareHARP vs PEP

HARP vs PEP: Dividend Comparison 2026

HARP yields 8.69% · PEP yields 3.63%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PEP wins by $106.4K in total portfolio value· pulled ahead in Year 6
10 years
HARP
HARP
● Live price
8.69%
Share price
$23.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$35.6K
Annual income
$1,504.59
Full HARP calculator →
PEP
PepsiCo Inc.
● Live price
3.63%
Share price
$156.82
Annual div
$5.69
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$141.9K
Annual income
$61,875.67
Full PEP calculator →

Portfolio growth — HARP vs PEP

📍 PEP pulled ahead of the other in Year 6

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHARPPEP
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HARP + PEP cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HARP pays
PEP pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HARP
Annual income on $10K today (after 15% tax)
$738.81/yr
After 10yr DRIP, annual income (after tax)
$1,278.90/yr
PEP
Annual income on $10K today (after 15% tax)
$308.41/yr
After 10yr DRIP, annual income (after tax)
$52,594.32/yr
At 15% tax rate, PEP beats the other by $51,315.42/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HARP + PEP for your $10,000?

HARP: 50%PEP: 50%
100% PEP50/50100% HARP
Portfolio after 10yr
$88.7K
Annual income
$31,690.13/yr
Blended yield
35.71%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PEP right now

HARP
Analyst Ratings
7
Buy
2
Hold
Consensus: Buy
Price Target
$700.00
+2942.2% upside vs current
Range: $700.00 — $700.00
Altman Z
0.4
Piotroski
2/9
PEP
Analyst Ratings
1
Strong
15
Buy
27
Hold
1
Sell
Consensus: Hold
Price Target
$172.43
+10.0% upside vs current
Range: $156.00 — $191.00
Altman Z
3.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HARP buys
0
PEP buys
0
No recent congressional trades found for HARP or PEP in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHARPPEP
Forward yield8.69%3.63%
Annual dividend / share$2.00$5.69
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.4%
Portfolio after 10y$35.6K$141.9K
Annual income after 10y$1,504.59$61,875.67
Total dividends collected$11.9K$123.0K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyHold
Analyst price target$700.00$172.43

Year-by-year: HARP vs PEP ($10,000, DRIP)

YearHARP PortfolioHARP Income/yrPEP PortfolioPEP Income/yrGap
1$11,569$869.19$10,849$509.42+$720.00HARP
2$13,319$939.79$11,969$750.47+$1.4KHARP
3$15,262$1,011.14$13,500$1,124.14+$1.8KHARP
4$17,414$1,082.88$15,680$1,721.66+$1.7KHARP
5$19,787$1,154.69$18,929$2,715.34+$858.00HARP
6← crossover$22,399$1,226.25$24,023$4,450.80$1.6KPEP
7$25,264$1,297.27$32,510$7,669.92$7.2KPEP
8$28,400$1,367.49$47,709$14,093.60$19.3KPEP
9$31,824$1,436.67$77,415$28,083.48$45.6KPEP
10$35,557$1,504.59$141,922$61,875.67$106.4KPEP

HARP vs PEP: Complete Analysis 2026

HARPStock

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian and pancreatic cancer, and other mesothelin-expressing tumors. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Full HARP Calculator →

PEPConsumer Staples

PepsiCo, Inc. manufactures, markets, distributes, and sells various beverages and convenient foods worldwide. The company operates through seven segments: Frito-Lay North America; Quaker Foods North America; PepsiCo Beverages North America; Latin America; Europe; Africa, Middle East and South Asia; and Asia Pacific, Australia and New Zealand and China Region. It provides dips, cheese-flavored snacks, and spreads, as well as corn, potato, and tortilla chips; cereals, rice, pasta, mixes and syrups, granola bars, grits, oatmeal, rice cakes, simply granola, and side dishes; beverage concentrates, fountain syrups, and finished goods; ready-to-drink tea, coffee, and juices; dairy products; and sparkling water makers and related products. It serves wholesale and other distributors, foodservice customers, grocery stores, drug stores, convenience stores, discount/dollar stores, mass merchandisers, membership stores, hard discounters, e-commerce retailers and authorized independent bottlers, and others through a network of direct-store-delivery, customer warehouse, and distributor networks, as well as directly to consumers through e-commerce platforms and retailers. The company was founded in 1898 and is headquartered in Purchase, New York.

Full PEP Calculator →
📬

Get this HARP vs PEP comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HARP vs SCHDHARP vs JEPIHARP vs OHARP vs KOHARP vs MAINHARP vs MOHARP vs PMHARP vs GIS

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.